In urology, the main indication for radical cystectomy is muscle-invasive bladder cancer (MIBC) [1]. Radical cystectomy for MIBC is often accompanied by pelvic lymph node dissection (PLND). Extended PLND can potentially improve survival through the eradication of micrometastatic disease and improved pathologic staging since at the time of cystectomy, up to 25% of patients harbor lymph node deposits [2]. The first ever radical cystectomy was performed in 1887. Since then, open radical cystectomy has been the gold standard treatment for muscle-invasive bladder cancer (MIBC) [3]. A CT image of an invasive bladder tumor and an endoscopic view of a bladder tumor with extension into the urethra are shown in Figure 1.

With the advent of laparoscopic surgery, the first laparoscopic radical cystectomy was performed in 1993 [4]. However, despite the advent of laparoscopic surgery in urology, open radical cystectomy with lymphadenectomy (ORCL) has remained the treatment of choice for MIBC mainly because the long-term functional and oncologic outcomes of patients who underwent laparoscopic radical cystectomy with lymphadenectomy (LRCL) have been under investigation ever since [3]. Nevertheless, in 2012, Aboumarzouk et al. predicted that LRCL will one day be a viable alternative to ORCL once the steep learning curve is overcome [5]. With the recent advancements in knowledge and technology, LRCL is carried out more frequently and with spectacular results [6]. In 2015, Nosov et al. reported that major complication rates were similar between open radical cystectomy and laparoscopic radical cystectomy and that laparoscopic cystectomy was associated with a lower rate of minor complications than open cystectomy. They also reported that it was safer and associated with lower blood loss, decreased postoperative ileus, and lower length of stay compared with open radical cystectomy [7]. However, in resource-limited settings such as sub-Saharan Africa, laparoscopic procedures are not commonly performed. Thus, our study aims to demonstrate the efficacy, safety, and outcome of LRCL in a single urology center in Douala, Cameroon.

This is a prospective study carried out at the Centre medico-chirugical d’urologie in Douala, Cameroon, from 2015 to 2019. We included all patients with muscle-invasive bladder cancer who were scheduled to undergo LRCL at our center. We excluded patients with incomplete medical records and patients who were discharged against medical advice. In the end, 12 eligible patients were included in our study. We obtained patients’ information by directly interviewing them and consulting their clinical records. We collected relevant data on each patient’s age, sex, tumor size, American Society of Anesthesiologists classification, tumor location, presence or absence of neoadjuvant chemotherapy with cisplatin, histological classification before surgery, surgery duration, blood loss during surgery, histological classification after surgery, presence or absence of metastases, locations of metastases if present, preservation or not of blood vessels and nerves, type of derivation (Studer or Bricker) done, postoperative complications encountered, duration of postoperative hospitalization, tumor recurrence, date of tumor recurrence, location of recurrence, neoadjuvant chemotherapy, date of commencement of neoadjuvant chemotherapy, patient’s outcome (alive or dead), date of demise, and date of the last follow-up.

We included a total of 12 patients (ten men and two women) aged 32 years to 75 years with a median age of 61.5 [52.8 - 68.5] years. The tumor diameters ranged from 2 cm to 5 cm, with a mean diameter of 3.75 ± 1.06 cm. The tumors were located at the right lateral surface of the kidney in 3 (25%) patients, at the left lateral surface of the kidney in 2 (16.67%) patients, and at both lateral surfaces, the dome of the kidney, bladder neck/prostatic urethra, bladder neck/anterior surface of the kidney, left lateral surface/anterior surface of the kidney, right meatus/right lateral surface, and left meatus/left pelvis in one (8.33) patient each. Four (33.33%) of the twelve patients received neoadjuvant chemotherapy. According to the preoperative histological findings, six (50%) patients had tumors of grade pT2G3N0M0, three (25%) had tumors of grade pT2G2N0M0, two (16.67%) had tumors of grade pT3G2N1M0, and one (8.33%) had tumors of grade pT2G3N1M0. According to the classification of the American Society of Anesthesiologists (ASA), six (50%) patients belonged to grade 3, five (41.67%) belonged to grade 2, and one (8.33%) belonged to grade 1. The sociodemographic and preoperative details of the study participants are presented in Table 1.

All patients were put under general anesthesia during surgery. The surgery duration ranged from 180 minutes to 305 minutes with a mean duration of 242.08 ± 45.85 minutes. Blood vessels and nerves were preserved in 4 (33.33%) of the participants. The estimated blood loss during surgery ranged from 175 ml to 620 ml with a median value of 325 [260 - 465] ml. The resected cancerous tissues underwent histopathological analyses. The type of cancer identified was transitional cell carcinoma in 10 (83.33%) and epidermoid carcinoma in 2 (16.67%) cases. According to the histological classification, four (33.33%) patients had cancers of type pT2G3N0M0, three (25%) had cancers of type pT2G2N0M0, two (16.67%) had tumors of type pT3G2N1M0, and one each (8.33%) had tumors of grades pT3G2N1M0, pT3G3N1M1, and pT2G1N0M0. Four patients (33.33%) had metastases. These metastases were located in the ganglions only in three (75%) patients and in the ganglions and prostate in one (25%) patient. Bricker’s ileal conduit urinary diversion was performed in 10 (83.33%) patients while the Studer neobladder was used in two (16.67%) patients. The operative details of the study participants are presented in Table 2.

The duration of hospitalization ranged from 5 days to 10 days with a mean duration of 6 ± 1.48 days. Only one (8.33%) patient had a postoperative complication, which was rectal perforation. Two (16.67%) patients experienced a recurrence of the condition, and both of them ended up dying. The time-lapse till recurrence was 225 days in one patient and 256 days in the other, which gives a mean time-lapse of 240.5 ± 21.92 days. Three (25%) patients received adjuvant chemotherapy. Normally, all four patients with metastases were supposed to receive adjuvant chemotherapy; however, one of them had a poor general state that represented a contraindication to adjuvant chemotherapy. This particular patient died not long after. Six (50%) patients ended up dying while the other six (50%) survived. The follow-up duration for the deceased patients ranged from 200 days to 494 days with a median value of 278 [202 - 326] days. For those who survived, the follow-up duration ranged from 390 days to 2183 days with a median duration of 715 [478 - 1727] days. The postoperative details of the study participants are presented in Table 3.

Kaplan-Meier survival analyses revealed that the median overall survival was 486 days one-year overall survival rate was 58.33% while the five-year overall survival rate was 46.47%. The overall survival curve is presented in Figure 4.

This study aimed to evaluate the oncologic results and the place of laparoscopic cystectomy in the management of bladder cancer in a single urology center in Douala, Cameroon. We recruited ten patients with a median age of 61.5 [52.8 - 68.5] years, which is similar to the mean age of 69.4 years reported by Miyamoto and Epstein [8]. This similarity is explained by the fact that bladder cancer is a condition that occurs in older people, and muscle-invasive bladder cancer usually occurs in people of that age group. The mean tumor diameter in our

study was 3.75 ± 1.06 cm, which is in line with the findings of Tully et al. who reported having more tumors with diameters of more than 3 cm than those with diameters of less than 3 cm in their study [9]. This large tumor was expected since bladder tumors are usually not muscle-invasive at the onset. With time, they grow and invade the bladder muscle, at which point their dimensions are higher. Ten (83.33%) of the patients in our study had transitional cell carcinoma, which is expected as this histological type reportedly accounts for 95% of all bladder cancers [10]. Four patients (33.33%) had metastases. This is higher than the 10% - 15% reported by Park et al. in 2014 [11]. The percentage reported by Park et al. is lower because it applies only to cases in which the tumor is recurring whereas our percentage applies to all cases. Also, Park et al. recruited more

patients than we did in our study, which makes their findings likely to differ from ours. Three patients (25%) received adjuvant chemotherapy. Normally, all four patients with metastases were supposed to receive adjuvant chemotherapy; however, one of them had a poor general state that represented a contraindication to adjuvant chemotherapy. The median estimated blood loss in our study was 325 [260 - 465] ml, which is lower than the mean value of 249.69 ± 95.59 milliliters reported by Aboumarzouk et al. in 2012 [5]. This difference is probably due to the fact that Aboumarzouk et al. carried out their study at a specialized center where such laparoscopic procedures are carried out regularly and by the same surgeon over five years, which means the surgeon and surgical team in their study were probably more experienced than those in our study considering how rarely this procedure is performed in our setting. As such, they were capable of carrying out these procedures with less blood loss. The mean surgery duration in our study was 242.08 ± 45.85 minutes, which is higher than the 166 minutes reported by Simonato et al. in 2003 [12]. The difference can be explained by the fact that Simonato et al. performed six orthotopic ileal neobladders, two sigmoid ureterostomies, and two cutaneous ureterostomies, whereas we carried out ten Bricker’s ileal conduit urinary diversions, which is a technique that takes significantly longer, out of our twelve surgical procedures. The mean postoperative hospital stay in our study was 6 ± 1.48 days, which is similar to the overall mean value of 7 days reported by Simonato et al. [12]. This similarity can be explained by the fact that they, just like us, recruited a small number of patients (ten patients compared to our twelve) and had a minimal rate of postoperative complications. The absence of major postoperative complications, which is generally a feature of laparoscopic surgery, allows for short postoperative hospitalization durations. The five-year overall survival rate in our study was 46.47%, which is higher than the three-year survival rate of 40% reported by Çelen et al. in 2020 [13]. This difference is due to the fact that Çelen et al. carried out their study on patients with more advanced bladder cancer (stages T3 and T4); as such, the overall survival of the patients in their study was expected to be lower than that of patients in our study.

The main limitation of our study was its small sample size, which is probably due to the fact that laparoscopic surgery has not yet been fully integrated into daily medical practice in our setting. As such, patients with such conditions tend to opt for open surgery as they still regard laparoscopic surgery as being experimental. We recommend that more studies with larger samples be carried out on this topic in the future to further investigate our findings.

Laparoscopic cystectomy is a mini-invasive technique associated with good cancer control. When performed by well-trained staff using specialized equipment, it can be a safe and effective method of managing muscle-invasive bladder cancer.

The authors thank Health Search Association for their contribution to this work.

The authors did not receive any external funding for this study.

The authors have no conflicting interests to declare.

Kamadjou, C., Eyongeta, D.E., Kameni, A.W., Mpah, H.M., Kamga, J., Ngninkeu, B.N. and Angwafo, F. (2022) Transperitoneal Laparoscopic Cystoprostatectomy for Muscle Invasive Bladder Cancer: Results and Oncologic Outcomes in a Single Center in Douala Cameroon. Surgical Science, 13, 529-540. https://doi.org/10.4236/ss.2022.1311061